HU000025975T2

(19) **HU**

(11) Lajstromszám: **E 025 975**

(13) **T2**

MAGYARORSZÁG
Szellemi Tulajdon Nemzeti Hivatala

EURÓPAI SZABADALOM
SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 11 722435**
(22) A bejelentés napja: **2011. 05. 30.**

(96) Az európai bejelentés bejelentési száma:
EP 20110722435
(97) Az európai bejelentés közzétételi adatai:
EP 2595685 A1 **2012. 01. 26.**
(97) Az európai szabadalom megadásának meghirdetési adatai:
EP 2595685 B1 **2015. 10. 21.**

(51) Int. Cl.: ***A61M 15/08*** *(2006.01)*
A61F 5/56 *(2006.01)*
A61M 11/00 *(2006.01)*
A61M 15/00 *(2006.01)*

(86) A nemzetközi (PCT) bejelentési szám:
PCT/EP 11/058844
(87) A nemzetközi közzétételi szám:
WO 12010358

(30) Elsőbbségi adatok:
842267 **2010. 07. 23.** **US**

(72) Feltaláló(k):
ARNFELDT MOLLER, René, DK-2840 Holte (DK)

(73) Jogosult(ak):
Tannermedico A/S, 2970 Horsholm (DK)

(74) Képviselő:
Iványka Gábor, ARINOVA Szabadalmi és Védjegy Iroda, Budapest

(54) **Orrspray készülék**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 2 595 685 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
21.10.2015 Bulletin 2015/43

(21) Application number: **11722435.2**

(22) Date of filing: **30.05.2011**

(51) Int Cl.:
A61M 15/08 *(2006.01)* ***A61M 11/00*** *(2006.01)*
A61M 15/00 *(2006.01)* *A61F 5/56* *(2006.01)*

(86) International application number:
PCT/EP2011/058844

(87) International publication number:
WO 2012/010358 (26.01.2012 Gazette 2012/04)

(54) **Nasal spray apparatus**

Nasenspray

Appareil de type spray nasal

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **23.07.2010 US 842267**

(43) Date of publication of application:
29.05.2013 Bulletin 2013/22

(73) Proprietor: **Tannermedico A/S**
2970 Hørsholm (DK)

(72) Inventor: **ARNFELDT MØLLER, René**
DK-2840 Holte (DK)

(74) Representative: **Nordic Patent Service A/S**
Højbro Plads 10
1200 Copenhagen K (DK)

(56) References cited:
FR-A- 1 240 547
US-A- 4 150 744
US-A1- 2002 134 374
US-A1- 2009 137 950
US-A1- 2009 157 037

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 595 685 B1

Printed by Jouve, 75001 PARIS (FR)

Description

BACKGROUND OF THE INVENTION

[0001] The present disclosure generally relates to administering a substance to the throat. More particularly, the aspects of the disclosed embodiments relate to administering a substance to the throat via the nose using a blow-fill-mold style bottle.

[0002] Devices are available for administering active substances or substances to the body, particularly through the throat, lungs or sinuses. These devices generally include containers that have a main chamber holding the desired contents and a head portion that is inserted into the nose or mouth. By squeezing the container, the substance is released into the nose or mouth. In some cases, the device has a tab or seal that must be broken in order to release the substance. A relatively narrow neck on the device can form the outlet channel from the main chamber into the head portion. This outlet channel can sealed by a frangible membrane that is typically formed by placing a crimp, tab or seal across the head portion during the molding and sealing process. At the time of use, the head portion is broken away from the main chamber portion, thus opening the outlet channel and allowing removal or dispensing of the contents. When the substance is being administered orally, the user will typically inhale at roughly the same time as the substance is released in order to force the medicine into, or further into, the sinus cavity, throat or lungs.

[0003] The blow-fill-seal process (BFS process), also referred to herein as blow-fill-mold, is a single operation which produces sterile containers. Bottles or vials made from materials such as from thermoplastic, are blown to a desired shape and immediately on cooling are filled aseptically with a desired fluid and hermetically sealed. The containers that are produced by the blow-fill-seal process are generally referred to herein as "BFS containers." The blow-fill seal process generally produces compact, easy-to-use substance dispensing devices that can be used to deliver substance to the throat, lungs or sinuses.

[0004] Snoring is a serious problem for a large segment of the population. Snoring is a sleep disorder that can range from mild to severe in humans. Mild cases may result in no more than fitful sleep by the sufferer, while severe cases can cause disturbance of the sleep of others, and may result in insufficient inhalation of oxygen by the sufferer, apnea and, in extreme cases, death.

[0005] Remedies to alleviate the symptoms of snoring can range from surgery to a variety of substances. Although surgery has been proven to be somewhat effective, it is a radical and expensive approach that is subject to all the usual risks associated with surgery. Drugs are available by prescription for the treatment of the symptoms of snoring. Other snoring management techniques can include for example, mechanical aids, nasal strips and anti-snoring sprays. Anti-snoring sprays can tend to be ineffective unless applied repeatedly during the night. Additionally, device sterilization is a concern when administering anti-snoring sprays due to the potential for infection since the sprays are introduced directly into the lungs in a manner that at least partially bypasses the patient's natural defense mechanisms.

[0006] Accordingly, it would be desirable to provide a system that addresses at least some of the problems identified above.

[0007] An exemple of prior art device is given in FR 1 240 547 A.

BRIEF DESCRIPTION OF THE INVENTION

[0008] As described herein, the exemplary embodiments of the present invention overcome one or more of the above or other disadvantages known in the art.

[0009] In one aspect, the disclosed embodiments are directed to a pharmaceutical product in the form of an anti-snoring substance. In one embodiment, the product includes a container containing the anti-snoring substance; the anti-snoring substance being in the form of a solution pre-concentrate; the container being made by a blow-fill-seal technology, wherein the container material is Polyethylene or Polypropylene; the container including a body portion containing the anti-snoring substance and a fluid outlet portion configured to deliver the anti-snoring substance.

[0010] Disclosed is also a method for administering an anti-snoring substance. The method includes sealing a unit dose of the anti-snoring substance in a container made by a blow-fill-seal technology; opening the unit dose; administering the anti-snoring substance to a nasal passage of a patient while a head of the patient is in a substantially backward tilted position in order for the substance to reach a throat of the patient, wherein the anti-snoring substance is delivered into the nasal passage in the form of a jet stream.

[0011] In a further aspect, the disclosed embodiments are directed to a nasal spray apparatus. In one embodiment, the apparatus includes a nasal preparation containing an anti-snoring substance; a container having an opening that provides access to an interior cavity, which container is operable to hold the anti-snoring substance within the interior cavity; a pump dispenser mounted on the container in a manner that closes the opening; wherein the container and pump dispenser are manufactured by a blow-fill-mold process.

[0012] These and other aspects and advantages of the disclosed embodiments will become apparent from the following detailed description considered in conjunction with the accompanying drawings. It is to be understood, however, that the drawings are designed solely for purposes of illustration and not as a definition of the limits of the invention, for which reference should be made to the appended claims. Moreover, the drawings are not necessarily drawn to scale and that, unless otherwise indicated, they are merely intended to conceptually illus-

trate the structures and procedures described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In the drawings:

Fig. 1 illustrates an exemplary dispensing device incorporating aspects of the present disclosure.

Fig. 2 illustrates a use application of the dispensing device incorporating aspects of the disclosed embodiments.

DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS OF THE INVENTION

[0014] Referring now to Fig. 1, a device 102 for the nasal or oral delivery of a substance is shown. The aspects of the disclosed embodiments are generally directed to the administration of an anti-snoring substance or medicament to a patient with a device manufactured using blow-fill-seal or blow-fill-mold technology. The device 102 shown in Fig. 1 is part of an ampule pack 100. In one embodiment, the device 102 comprises a sealed flexible container or body portion 104 containing the substance or medicament. The device 102 is typically manufactured using a blow-fill-seal or blow-fill-mold technique.

[0015] As shown in Fig. 1, the device 102 generally comprises a body portion 104 and a fluid outlet portion 106. The body portion 104 is configured to hold the nasal preparation, also referred to herein as the anti-snoring substance. In one embodiment, the device 102 includes a tab portion 108, which is generally configured to be of a twist off type. A frangible member 110 can be included on the fluid outlet portion 106 near or as part of the tab portion 108, to allow the tab portion 108 to be easily removed.

[0016] During the blow-fill-seal process, the device 102 is substantially filled with the anti-snoring substance when oriented in the vertical plane and sealed. When the tab 108 is removed, the substance can be dispensed, such as shown in Fig. 2. In this embodiment, the substance is generally dispensed by allowing the substance to exit from the fluid outlet portion 106 as the device 102 is positioned with the fluid outlet portion 106 oriented in a substantially downward direction. In this example, the body portion 104 can be compressed to force or urge the substance from the body portion 104 and out of the fluid outlet portion 106 in the form of a jet stream, rather than a spray or atomization.

[0017] In one embodiment, the substance comprises an anti-snoring solution named ASONOR® and manufactured by TannerMedico A/S, Denmark. The solution comprises Sodium Chloride, Glycerol, Polysorbate and Edetatesodium. Potassium sorbate can be added as preservative. During the manufacturing process, the solution is filled into the body portion 104 as part of the Blow-Fill-Seal process, as otherwise known in the art. In one embodiment, the containers 102 are plastic Polypropylene or Polyethylene containers. In alternate embodiments, the containers 102 can comprise any suitable container for use in the Blow-Fill-Seal process. Each container forms a single unit dose.

[0018] A method of administering the substance is described with respect to Fig. 2. As shown in Fig. 2, the head 200 of the user is generally tilted in a backwards or rearwards direction, such as the direction A shown in Fig. 2, from a substantially upright position, so that the nose 202 is in a substantially horizontal or slightly backward tilted position relative to the ground 204. Generally, the head 200 needs to be tilted backwards far enough, for a period of time, to allow the substance to travel through the nasal passages 206 to the throat area 208. By tilting the head 200 backwards, gravity will assist in delivering the liquid substance to the throat area 208 through the nasal passages 206.

[0019] Once the head 200 is in the tilted back position as is shown in Fig. 2, the end 106 of device 100 being used is placed in or near the opening of the nostril 210. The container 220 is then squeezed to deliver the substance into the nasal passage 206 and to the throat passage 208. The container 220 is squeezed a sufficient number of times until the substance is felt in the throat passage 208 or the entire substance is expended. The process is repeated for each of the nasal passages 206. Generally, three to four pumps into each nostril 210 is sufficient.

[0020] The liquid substance is not intended to remain in the nasal passages 206, as the benefits of this anti-snoring substance are primarily realized from the substance reaching the throat passage 208.

[0021] The aspects of the disclosed embodiments provide an effective treatment against snoring. An anti-snoring substance, and in particular ASONOR®, is administered into the nasal passages using a blow-fill mold style bottle. By incorporating a jet-stream style outlet nozzle, rather than a spray or atomization, the substance does not stay in the nose, but is rather delivered to the throat. This advantageously allows the substance to begin working sooner.

[0022] Moreover, it is expressly intended that all combinations of those elements and/or method steps which perform substantially the same function in substantially the same way to achieve the same results are within the scope of the invention. Moreover, it should be recognized that structures and/or elements shown and/or described in connection with any disclosed form or embodiment of the invention may be incorporated in any other disclosed or described or suggested form or embodiment as a general matter of design choice. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.

Claims

1. A pharmaceutical product comprising: a container containing a liquid anti-snoring substance; the liquid anti-snoring substance being in the form of a solution pre-concentrate; the container being made by a blow-fill-seal technology, wherein the container material is polyethylene or polypropylene; the container including a body portion containing the liquid anti-snoring substance and a fluid outlet portion configured to deliver the liquid anti-snoring substance; **characterized in that** the fluid outlet portion is configured to deliver the liquid anti-snoring substance directly into a nasal passage in the form of a jet stream.

2. The product according to claim 1 wherein the fluid outlet portion comprises a jet stream nozzle.

3. The product according to claim 1 or 2 wherein the container is a squeeze device.

4. The product according to any of the claims 1 to 3 wherein the liquid anti-snoring substance is administered through a nasal passage to the throat of a patient.

5. The product according to any of the claims 1 to 4 wherein the liquid anti-snoring substance is an anti-snoring solution comprising sodium chloride, glycerol, polysorbate and edetate sodium, and, optionally, potassium sorbate as preservative.

6. The product according to any of claims 1-5 wherein the container includes a unit dose of the anti-snoring substance.

7. The product according to claim 6, wherein the unit dose is delivered in multiple delivery increments.

8. A nasal spray apparatus comprising: a nasal preparation containing a liquid anti-snoring substance; a container having an opening that provides access to an interior cavity, which container is operable to hold the liquid anti-snoring substance within the interior cavity; a pump dispenser mounted on the container in a manner that closes the opening; wherein the container and pump dispenser are manufactured by a blow-fill-mold process; **characterized in that** the container is configured to deliver the liquid anti-snoring substance directly into a nasal passage in the form of a jet stream.

9. The apparatus of claim 8 wherein the container further comprises a nozzle and nozzle tip, and wherein the nozzle tip delivers the liquid anti-snoring substance directly into the nasal passage in the form of a jet stream.

10. The apparatus of claim 8 or 9 wherein the liquid anti-snoring substance is delivered by the jet stream through the nasal passage into the throat passage of a patient.

11. The apparatus of claim 8, 9, or 10 wherein the apparatus includes a single dose of the liquid anti-snoring substance and is disposable.

12. A pharmaceutical product in the form of a liquid anti-snoring substance wherein the liquid anti-snoring substance is an anti-snoring solution comprising sodium chloride, glycerol, polysorbate and edetate sodium, and, optionally, potassium sorbate as preservative, for use in the treatment of snoring and apnea **characterized in that** the anti-snoring solution is administered directly into a nasal passage (206) of a patient as a jet stream while the head (200) of the patient is in a substantially backward tilted position in order for the anti-snoring solution to reach the throat area (208) through the nasal passage (206).

Patentansprüche

1. Pharmazeutisches Produkt, das umfasst: einen Behälter, der eine flüssige Anti-Schnarch-Substanz enthält; wobei die flüssige Anti-Schnarch-Substanz in der Form eines Lösungsvorkonzentrats vorliegt; wobei der Behälter durch die Blasen-Füllen-Verschließen Technologie hergestellt ist, wobei das Behältermaterial aus Polyethylen oder Polypropylen besteht; wobei der Behälter einen Körperabschnitt, der die flüssige Anti-Schnarch-Substanz enthält, und einen Fluidauslassabschnitt enthält, der konfiguriert ist, um die flüssige Anti-Schnarch-Substanz abzugeben; **dadurch gekennzeichnet, dass** der Fluidauslassabschnitt konfiguriert ist, um die flüssige Anti-Schnarch-Substanz direkt in einen Nasengang in der Form eines Strahlstroms abzugeben.

2. Produkt nach Anspruch 1, wobei der Fluidauslassabschnitt eine Strahlstromdüse umfasst.

3. Produkt nach Anspruch 1 oder 2, wobei der Behälter eine Quetschdruckvorrichtung ist.

4. Produkt nach einem der Ansprüche 1 bis 3, wobei die flüssige Anti-Schnarch-Substanz durch einen Nasengang in den Hals eines Patienten verabreicht wird.

5. Produkt nach einem der Ansprüche 1 bis 4, wobei die flüssige Anti-Schnarch-Substanz eine Anti-Schnarch-Lösung ist, die Natriumchlorid, Glycerol, Polysorbat und Natriumedetat und wahlweise Kaliumsorbat als Konservierungsstoff umfasst.

6. Produkt nach einem der Ansprüche 1 bis 5, wobei der Behälter eine Einheitsdosis der Anti-Schnarch-Substanz enthält.

7. Produkt nach Anspruch 6, wobei die Einheitsdosis in mehrfachen Abgabeinkrementen abgegeben wird.

8. Nasensprayvorrichtung, die umfasst: eine Nasenpräparation, die eine flüssige Anti-Schnarch-Substanz enthält; einen Behälter mit einer Öffnung, die einen Zugang zu einem inneren Hohlraum bereitstellt, wobei der Behälter betreibbar ist, um die flüssige Anti-Schnarch-Substanz innerhalb des inneren Hohlraums zu halten; einen Pumpenspender, der auf dem Behälter in einer Weise befestigt ist, die die Öffnung schließt; wobei der Behälter und der Pumpenspender durch ein Blasen-Füllen-Formverfahren hergestellt sind; **dadurch gekennzeichnet, dass** der Behälter konfiguriert ist, um die flüssige Anti-Schnarch-Substanz direkt in einen Nasengang in der Form eines Strahlstroms abzugeben.

9. Vorrichtung nach Anspruch 8, wobei der Behälter ferner eine Düse und eine Düsenspitze umfasst, und wobei die Düsenspitze die flüssige Anti-Schnarch-Substanz direkt in den Nasengang in der Form eines Strahlstroms abgibt.

10. Vorrichtung nach Anspruch 8 oder 9, wobei die flüssige Anti-Schnarch-Substanz durch den Strahlstrom durch den Nasengang in den Halskanal eines Patienten abgegeben wird.

11. Vorrichtung nach Anspruch 8, 9 oder 10, wobei die Vorrichtung eine Einzeldosis der flüssigen Anti-Schnarch-Substanz enthält und wegwerfbar ist.

12. Pharmazeutisches Produkt in der Form einer flüssigen Anti-Schnarch-Substanz, wobei die flüssige Anti-Schnarch-Substanz eine Anti-Schnarch-Lösung ist, die Natriumchlorid, Glycerol, Polysorbat und Natriumedetat und wahlweise Kaliumsorbat als Konservierungsstoff umfasst, für eine Verwendung in der Behandlung von Schnarchen und Atemstillstand (Apnoe), **dadurch gekennzeichnet, dass** die Anti-Schnarch-Lösung direkt in einen Nasengang (206) eines Patienten als ein Strahlstrom verabreicht wird, während sich der Kopf (200) des Patienten im Wesentlichen in einer nach hinten geneigten Position befindet, damit die Anti-Schnarch-Lösung den Halsbereich (208) durch den Nasengang (206) erreicht.

Revendications

1. Produit pharmaceutique comprenant : un récipient contenant une substance anti-ronflement liquide ; la substance anti-ronflement liquide étant sous la forme d'un pré-concentré de solution ; le récipient étant fabriqué par une technologie de formage-remplissage-scellage, le matériau de récipient étant du polyéthylène ou du polypropylène ; le récipient comprenant une portion de corps contenant la substance anti-ronflement liquide et une portion de sortie de fluide configurée pour administrer la substance anti-ronflement liquide ; **caractérisé en ce que** la portion de sortie de fluide est configurée pour administrer la substance anti-ronflement liquide directement dans un passage nasal sous la forme d'un écoulement en jet.

2. Produit selon la revendication 1, la portion de sortie de fluide comprenant une buse d'écoulement en jet.

3. Produit selon la revendication 1 ou 2, le récipient étant un dispositif à compression.

4. Produit selon l'une quelconque des revendications 1 à 3, la substance anti-ronflement liquide étant administrée par un passage nasal vers la gorge d'un patient.

5. Produit selon l'une quelconque des revendications 1 à 4, la substance anti-ronflement liquide étant une solution anti-ronflement comprenant du chlorure de sodium, du glycérol, du sodium de polysorbate et d'édetate, et, éventuellement, du sorbate de potassium comme conservateur.

6. Produit selon l'une quelconque des revendications 1 à 5, le récipient comprenant une dose unitaire de la substance anti-ronflement.

7. Produit selon la revendication 6, la dose unitaire étant administrée par des augmentations d'administration multiples.

8. Appareil à pulvérisation nasale comprenant : une préparation nasale contenant une substance anti-ronflement liquide ; un récipient ayant une ouverture qui offre un accès à une cavité intérieure, lequel récipient peut fonctionner pour maintenir la substance anti-ronflement liquide au sein de la cavité intérieure ; une pompe distributrice montée sur le récipient d'une manière qui ferme l'ouverture ; le récipient et la pompe distributrice étant fabriqués par un processus de formage-remplissage-scellage ; **caractérisé en ce que** le récipient est configuré pour administrer la substance anti-ronflement liquide directement dans un passage nasal sous la forme d'un écoulement en jet.

9. Appareil selon la revendication 8, le récipient comprenant en outre une buse et un bec de buse, le bec de buse administrant la substance anti-ronflement

liquide directement dans le passage nasal sous la forme d'un écoulement en jet.

10. Appareil selon la revendication 8 ou 9, la substance anti-écoulement liquide étant administrée par un écoulement en jet au travers du passage nasal dans le passage de la gorge d'un patient.

11. Appareil selon la revendication 8, 9, ou 10, l'appareil incluant une dose unique de substance anti-ronflement liquide et étant jetable.

12. Produit pharmaceutique sous la forme d'une substance anti-ronflement liquide, la substance anti-ronflement liquide étant une solution anti-ronflment comprenant du chlorure de sodium, du glycérol, du sodium de polysorbate et d'édétate, et, éventuellement, du sorbate de potassium comme conservateur, à utiliser dans le traitement du ronflement et de l'apnée **caractérisé en ce que** la solution anti-ronflement est administrée directement dans un passage nasal (206) d'un patient comme un écoulement en jet tandis que la tête (200) d'un patient est dans une position essentiellement inclinée vers l'arrière afin que la solution anti-ronflement atteigne la zone de la gorge (208) à travers le passage nasal (206).




FIG. 1




FIG. 2

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- FR 1240547 A **[0007]**

ORRSPRAY KÉSZÜLÉK

Szabadalmi igénypontok

1. Gyógyászati termék, amely magában foglalja a következőket: egy tartályt, amely tartalmaz egy folyékony, horkolás elleni anyagot; ahol a folyékony, horkolás elleni anyag egy oldat-előkoncentrátum (angolul: „solution pre-concentrate") formájában áll rendelkezésre; ahol a tartály egy fúvás-töltés-lezárás technológia (angolul: „blow-fill-seal technology") révén van előállítva; ahol a tartály anyaga polietilén vagy polipropilén; ahol a tartály magában foglal egy törzs részt, amely tartalmazza a folyékony, horkolás elleni anyagot, és egy fluidum-kibocsátó részt, amely úgy van kialakítva, hogy legyen kibocsátva a folyékony, horkolás elleni anyag; **azzal jellemezve, hogy** a fluidum-kibocsátó rész úgy van kialakítva, hogy a folyékony, horkolás elleni anyag legyen kibocsátva közvetlenül egy orrjáratba egy futóáramlás (angolul: „jet stream") formájában.
2. Termék az 1. igénypont szerint, ahol a fluidum-kibocsátó rész magában foglal egy futóáramlás-fúvókát (angolul: „jet stream nozzle").
3. Termék az 1. vagy 2. igénypont szerint, ahol a tartály egy nyomókészülék.
4. Termék az 1.-től 3.-ig igénypontok bármelyike szerint, ahol a folyékony, horkolás elleni anyag egy orrjáraton keresztül van adagolva egy páciensnek a torkába.
5. Termék az 1.-től 4.-ig igénypontok bármelyike szerint, ahol a folyékony, horkolás elleni anyag egy horkolás elleni oldat, amely tartalmaz nátrium-kloridot, glicerint, poliszorbátot és nátrium-edetátot, és, opcionálisan, kálium-szorbátot tartósítószerként.
6. Termék az 1.-től 5.-ig igénypontok bármelyike szerint, ahol a tartály magában foglalja a horkolás elleni anyag egy egységdózisát.
7. Termék a 6. igénypont szerint, ahol az egységdózis többszörös adagolás növelésekkel van adagolva.
8. Orrspray készülék, amely magában foglalja a következőket: egy nazális készítményt, amely tartalmaz egy folyékony, horkolás elleni anyagot; egy tartályt, amely rendelkezik egy nyílással, amely rendelkezésre állít egy bementet egy belső üregbe, amely tartály működtethető úgy, hogy a folyékony, horkolás elleni anyag a belső üregen belül legyen tartva; egy pumpa adagolót, amely a tartályra van szerelve oly módon, hogy lezárja a nyílást; ahol a tartály és a pumpa adagoló egy fúvás-töltés-formaöntés eljárás (angolul: „blow-fill-mold process") révén vannak előállítva; **azzal jellemezve, hogy** a tartály úgy van kialakítva, hogy a folyékony, horkolás elleni anyag legyen kibocsátva közvetlenül egy orrjáratba egy futóáramlás (angolul: „jet stream") formájában.
9. Készülék a 8. igénypont szerint, ahol a tartály továbbá magában foglal egy fúvókát és egy fúvóka-csúcsot, és ahol a fúvóka-csúcs közvetlenül adagolja a folyékony, horkolás elleni anyagot az orrjáratba egy futóáramlás (angolul: „jet stream") formájában.
10. Készülék a 8. vagy 9. igénypont szerint, ahol a folyékony, horkolás elleni anyag a futóáramlás (angolul: „jet stream") révén van adagolva az orrjáraton keresztül egy páciensnek a torokjáratába.
11. Készülék a 8., 9. vagy 10. igénypont szerint, ahol a készülék magában foglalja a folyékony, horkolás elleni anyag egyetlen dózisát és eldobható.
12. Gyógyászati termék egy folyékony, horkolás elleni anyag formájában, ahol a folyékony, horkolás elleni anyag egy horkolás elleni oldat, amely tartalmaz nátrium-kloridot, glicerint, poliszorbátot és nátrium-edetátot, és, opcionálisan, kálium-szorbátot tartósítószerként, alkalmazás céljából a horkolás és apnoé (légzéskimaradás) kezelésében, **azzal jellemezve, hogy** a horkolás elleni oldat közvetlenül van adagolva egy páciens egy orrjáratába (206), mint egy futóáramlás (angolul: „jet stream"), mialatt a páciensnek a feje (200) egy lényegében hátrafelé dőlt pozícióban van azon célból, hogy a horkolás elleni oldat elérje a torok területét (208) az orrjáraton (206) keresztül.